Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation

PLUS THERAPEUTICS, INC.

Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.
Net loss $6.9M ($1.05 per share) vs $17.4M in Q1 2025 (post reverse split).
Revenue $1.0M from CPRIT grant and CNSide billings; operating loss $7.1M vs $3.5M year ago.
FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and ependymoma.
CNSide expanded payer coverage to ~81M lives including Blue Shield of California; unique PLA code secured.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $1.0 million, net income $6.9 million, or $1.05 per basic share, EPS $1.05 per basic share. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $1.0 million
Net income: $6.9 million, or $1.05 per basic share
EPS: $1.05 per basic share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

2026 public offering, partially offset by operating expenditures during the quarter and paydown of the investor liability at December 31, 2025 of $4.5 million • Recognized $1.0 million in revenue in the first quarter of 2026, including grant revenue from CPRIT for the advancement of REYOBIQ in LM and CNSide diagnostic billings, compared to $1.1 million in the

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-226747

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.